December 23, 2010
European Commission approves Novartis drug Tasigna® for treatment of patients with newly diagnosed Ph+ chronic myeloid leukemia
December 23, 2010
Novartis submits Bexsero®, a multi-component meningococcal B vaccine, for regulatory review in Europe
December 21, 2010
Novartis drug Tasigna® approved in Japan for treatment of patients with newly diagnosed Ph+ chronic myeloid leukemia
December 20, 2010
Novartis investigational JAK inhibitor INC424 data met primary endpoint in Phase III trial of patients with myelofibrosis
December 20, 2010
Novartis affirms commitment to Russia through USD 500 million multi-year healthcare investment
December 15, 2010
Novartis to become global leader in eye care, with agreement of 100% merger with Alcon
-
- Share buyback to be reactivated to minimize dilution to Novartis shareholders
-
December 09, 2010
Study of Novartis drug Zometa for potential new use in early breast cancer did not meet primary endpoint in overall study population
December 09, 2010
Study shows Novartis drug Afinitor® plus hormonal therapy delays disease progression in advanced metastatic breast cancer patients
December 06, 2010
Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
- LBH589 (panobinostat) shows sustained anticancer activity in Hodgkin lymphoma patients who relapse or are refractory after autologous stem cell transplant
- High unmet treatment need exists for patients who relapse or become refractory after initial treatment; patients are often in their mid-thirties or younger
- Worldwide regulatory filings are planned based on study findings
December 06, 2010
Longer-term Phase III data show Novartis drug Tasigna® continues to surpass Glivec® in slowing disease progression in patients with newly diagnosed CML
